Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
Nephrology · 2024
DOI: 10.1111/nep.14336 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nephrology, 2024. Verfasst von Philippa Trevella und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Kidney, Diabetic Nephropathies. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes (T2DM) with chronic kidney disease (CKD). This class of medication has demonstrated promising results in reducing albuminuria, preserving estimated glomerular filtration rate (eGFR), and mitigating cardiovascular (CV) risk, making them potential therapeutic options for individuals with CKD. The kidney protective effects of GLP‐1RAs extend beyond glycaemic control, and are thought to be attributed to their anti‐inflammatory, antioxidant, and natriuretic properties. Despite these promising findings, the use of GLP‐RAs has yet to be definitively shown to slow progression to chronic kidney failure, or reduce CV and kidney related death in people with T2DM and CKD. The Research Study to See How Semaglutide (a once weekly subcutaneous administered GLP‐1RA) Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW trial) was recently stopped because of efficacy. The primary end point for the FLOW trial consists of a composite endpoint of (i) onset of chronic kidney failure; (ii) death from kidney failure; (iii) cardiovascular death; and (iv) onset of a persistent ≥50% reduction in eGFR from baseline. It has also been reported by the sponsors of the trial that the primary end point of the trial was reduced by 24% with both CKD and CV outcomes contributing to risk reduction. In anticipation of the results of the FLOW trial being published, we review the current evidence surrounding kidney outcomes and proposed kidney protective pathways associated with GLP‐1RA use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
- Department of Endocrinology, Austin Health, Melbourne, Vitoria, Australia.
- Department of Medicine, Austin Health, Melbourne Medical School, Parkville, Victoria, Australia.
- Australian Centre for Accelerating Diabetes Innovations, School of Medicine, University of Melbourne, Parkville, Victoria, Australia.
- Department of Medicine St Vincent's Hospital Melbourne, University of Melbourne, Fitzroy, Vitoria, Australia.
ORCID-Profile: Richard J MacIsaac
Zitieren
APA
Trevella, P., Ekinci, E. I., & MacIsaac, R. J. (2024). Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists. Nephrology. https://doi.org/10.1111/nep.14336
Vancouver
Trevella P, Ekinci EI, MacIsaac RJ. Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists. Nephrology. 2024. doi:10.1111/nep.14336
BibTeX
@article{Trevella2024,
author = {Trevella, Philippa and Ekinci, Elif I and MacIsaac, Richard J},
title = {Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists},
journal = {Nephrology},
year = {2024},
doi = {10.1111/nep.14336}
}
EUVIMED